Thanks, good reminder of the differentiation between 2-73 and 3-71. As we know from the AD 2a study, higher concentration equates to generally better performance. I’d be very interested to see where 3-71 takes us.
Falconer....that has been the real conundrum......how do you treat 3-71, if it is just a more potent form of 2-73. You don't want to make your primary drug redundant. How does Anavex make them travel on separate tracks? How do you partner for 2-73's application for Alzheimer's if you have a more potent drug in the wings?
News 
Market Data 
Discover 
AI
